Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, September 16, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Results From Serum-Tumorautoantibody Profiling of Breast, Colon, Lung and Prostate Cancers Using a 16k Protein Array for Improving Minimal Invasive Diagnostics
  Videos

Return

Results From Serum-Tumorautoantibody Profiling of Breast, Colon, Lung and Prostate Cancers Using a 16k Protein Array for Improving Minimal Invasive Diagnostics
Austrian Institute of Technology GmbH

Andreas Weinhäusel, Senior Scientist, Austrian Institute of Technology GmbH

Abstract
In Europe there were an estimated 3.2 million new cases of cancer in 2008. The most commonly reported cases in Europe were colorectal cancers ( 13.6%), breast cancer (13.1%), lung cancer (12.2%) and prostate cancer (11.9%). These 4 big cancer entities make up more than 50% of all cancers. It is well accepted that early detection of cancer does improve patient survival, thus there is a pressing need to improve early cancer detection.  This can be best fulfilled by an easy and simple test suitable for minimal invasive testing. Tumour-associated antigens (TAA) can be detected prior to clinical diagnosis and thus would be ideal biomarkers for early detection of cancer using only a few microliters of a patient's serum.We have developed an 16k protein-microarray using the UNIPEX human cDNA expression library. During methods optimization we studies the influence of different serum and plasma sampling procedures and finally came up with an optimized protocol using purified IgG from samples for TAA profiling. This protocol enabled definition of TAA classifier panels with very promising classification success of patients versus controls for the big 4 cancer entities. Currently we set up targeted microarrays for validation of our screening results. In addition in silico design of antigenic peptides from sero-reactive clone-sequences has also been conducted and preliminary data enabled an improved classification compared to corresponding proteins. Thus multiplexed protein and peptide based serum-analyses could further improve cancer diagnostics

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Study Aims to Develop Breath Test for COPD
A new clinical iniative, lead by NYU Langone Medical Center, aims to determine a breath test’s effectiveness to identify volatile organic compounds (VOCs) in human breath that are biomarkers of chronic obstructive pulmonary disease (COPD).
More People Testing Positive for Chikungunya Virus in the U.S.
Clinical testing volume and positivity rate both grew after the first case of the infectious disease spread to Western Hemisphere this year.
Clinical Utility of Myriad myPath(TM) Melanoma Test Demonstrated
Test reduced indeterminate cases by 76 percent and changed treatment in 35 percent of cases.
Sequencing Identifies Gene Variant Responsible for Lupus
Research demonstrates it is feasible to identify the individual causes of lupus in patients by using DNA sequencing, allowing doctors to target specific treatments to individual patients.
Array Technology Could Screen for Emerging Viral Diseases
A microbe detection array technology could provide a new rapid method for public health authorities to conduct surveillance for emerging viral diseases.
Self-assembling Nanoparticle Could Improve MRI Scanning for Cancer Diagnosis
Scientists have designed the nanoparticle that targets tumours, to help doctors diagnose cancer earlier.
Researchers Invent Nanotech Microchip to Diagnose Type-1 Diabetes
The cheap, portable, microchip-based test could speed up diagnosis and enable studies of how the disease develops.
Significant Step Towards Blood Test for Alzheimer's
Scientists have identified a set of 10 proteins in the blood which can predict the onset of Alzheimer’s, marking a significant step towards developing a blood test for the disease.
Mass Spec Predicts Improved Response to Anti-HER2 Therapy in Breast Cancer
Immunohistochemistry is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives.
New App Helps Patients Ensure Best Outcome from Surgery
MySurgery - New and innovative approach to reducing risk in surgery.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv